American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2022. Diabetes Care. 2022;45(suppl 1):S125-S143. doi:10.2337/dc22-S009
2.
GersteinHCColhounHMDagenaisGR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3
3.
KanekoS. Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. touchREVEndocrinol. 2022;18(1):10-19. doi:10.17925/EE.2022.18.1.10
4.
Lyumjev [package insert]. Eli Lilly and Company; 2021.
5.
MarsoSPBainSCConsoliA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. doi:10.1056/NEJ-Moa1607141
6.
MarsoSPDanielsGHBrown-FrandsenK, et al. Liraglu-tide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322. doi:10.1056/NEJ-Moa1603827
7.
Mounjaro [package insert]. Eli Lilly and Company; 2022.
